Research suggests that combined hormonal contraceptives (CHC) have a similar safety profile to progestin-only contraceptives (POC) with regard to women with sickle cell disease and their risk of thromboembolism (TE). The study made use of population-level administrative claims data from publicly-insured US women with sickle cell disease. It was presented at the American Society of Hematology (ASH) Annual Meeting. Source: MDMag To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more